The Serce Dziecka Foundation is launching the InteliCardio training and research project. This initiative combines the fields of medicine and artificial intelligence (AI), offering the potential for a breakthrough in diagnosing congenital heart defects (CHD) in children.
Every day in Poland, 10 children are born with congenital heart defects, and one in five of them has a critical defect. Unfortunately, the low detection rate of these defects (only 30-50%) often leads to tragic consequences. With InteliCardio, there is a chance to change this! Artificial intelligence will aid in faster and more accurate detection of defects, enabling early intervention and saving many children’s lives.
The project was developed in collaboration with leading scientists in the field of congenital heart defect treatment (CHD). Its goal is to enhance the competencies and knowledge of doctors regarding the potential future use of AI to improve the diagnosis of congenital heart defects (CHD). The ability to utilize innovative IT tools will be crucial in the future for raising medical care standards and advancing the professional development of medical staff. Therefore, actions in this area must begin today.
Participants in the project—neonatologists and obstetricians—will learn how AI technologies can contribute to the earlier detection of defects, the potential of developed solutions to increase diagnostic accuracy, and the rapid processing of medical data.
We have invited leading Polish institutions specializing in congenital heart defects in fetuses to participate in the project:
The project will begin on August 30, 2024, with training at the PRO-FAMILIA Specialist Hospital.
The initiative is under the patronage and receives substantive support from the Polish Society of Prenatal Cardiology. The technologies used in the project are provided by a Polish company specializing in the use of AI for CHD diagnosis.
Detailed information about the project is available at www.intelicardio.pl.
We’re proud to announce that Prometheus MedTech.AI has advanced to the Top 40 startups worldwide in the prestigious K-Startup Grand Challenge…
From July 29 to August 1, 2025, our team took part in NeoHeart 2025 in San Diego, CA – the 10th…
We’re proud to announce that our innovative solution, Ultra Echo Scan (UES), has been selected among the Top 80 startups worldwide for the…
We are pleased to announce that the Prometheus MedTech.AI team has recently completed a productive visit to New York City, marking…
From the Top 10 Health Startups in Europe to the stage in Madrid — our team joined one of the world’s most prestigious innovation summits to connect, pitch, and share our mission.
We are proud to announce that UES Sp. z o.o. has received European Union funding to support the international expansion of our…
We are thrilled to announce that Prometheus MedTech.AI has been selected as one of the Top 10 startups in the Health category at South Summit…
Prometheus MedTech.AI was proud to participate in Wolves Summit 2025, one of Central and Eastern Europe’s leading events focused on…
We’re pleased to announce that Prometheus MedTech.AI (LPTW Sp. z o.o.) has been awarded a grant of 400,000 PLN as part…
We’re presenting at the “Revolutionizing Healthcare: AI, Technology and Impact” conference, showcasing Prometheus Med Tech.AI – our advanced platform designed…
We had the pleasure of participating in an event that attracted tremendous interest from the medical community and health tech…
We’re excited to share that our groundbreaking technology, Ultra Echo Scan, developed as part of the Prometheus Med Tech.AI project,…